This study confirmed that LXR activation may also inhibit PAH-induced cardiac hypertrophy and remodeling, and one of the mechanisms may be inhibition of NF-κB -mediated inflammatory and apoptotic pathways. This evidence concerns the gene NFKB1 and pulmonary arterial hypertension.